The University Hospital

Univ. Prof. Dr. med. Christian la Fougère

Univ. Prof. Dr. med. Christian la Fougère

Medical Director Nuclear Medicine and Clinical Molecular Imaging

Specialist in nuclear medicine
Additional qualification in X-ray diagnostics for nuclear medicine specialists
Specialist knowledge in radiation protection StrlSchV and RöV

Contact

Phone number: Secretariat: 07071 29-86553

Fax number: 07071 29-4601

E-mail address: christian.lafougere@med.uni-tuebingen.de

Clinic / Institute / Center

  • Hybrid imaging with PET/CT and PET/MR
  • SPECT/CT (oncology, cardiology, neurology, inflammation)
  • Special thyroid outpatient clinic
  • Radioiodine therapy for thyroid diseases
  • Radio-ligand therapy for prostate cancer (Lu-177 PSMA)
  • Peptide radio receptor therapy for NET and menigeomas
  • Local liver therapy (SIRT)
  • Radioligand therapy (mIBG, Zevalin)

  • Personal statement

    My main area of interest is the use of multimodal and multiparametric molecular imaging techniques with positron emission tomography (PET) to gain non-invasive insight into physiological (adaptive) and pathophysiological changes in various oncological and neurological diseases, with the aim of enabling individualized therapy stratification for patients. Furthermore, we develop new imaging probes (radiotracers) in close collaboration with the Department of Preclinical Imaging and Radiopharmacy, which we use and test translationally in the Department of Nuclear Medicine and Clinical Molecular Imaging. PET imaging plays a very important role in the various research initiatives and research networks at the University of Tübingen, including the IFIT Cluster of Excellence, the NCT South-West and the Centre for Personalized Medicine.

  • Multimodal and multiparametric neurological & neuro-oncological hybrid imaging
  • Translational imaging with PET/CT & PET/MR
    Use of new radiopharmaceuticals (first in man)
    Intelligent image analysis
  • Quantitative SPECT/CT
  • Translational oncology therapy approaches
  • Clinical study Phase II: Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET
  • Clinical study: Open-label, single-arm Phase I/II study to evaluate the safety, tolerability, biodistribution, radiation dosimetry and imaging of [18F]FPyGal-PET compared to in vitro methods for the assessment of senescence in oncology patients
  • seit 2023Member of the Board of the Comprehensive Cancer Center South-West
  • seit 2021Deputy Head of the ENETS Center of Excellence
  • seit 2020Chairman of the Fortüne Commission of the Tübingen Medical Faculty
  • 2017 - 2021Member of the Board of the German Society for Nuclear Medicine (DGN)
  • seit 2013Medical Director Nuclear Medicine and Clinical Molecular Imaging
  • 12/2010Habilitation in nuclear medicine
  • 2010 - 2013Head of Neurology and Neurooncology at the Clinic and Polyclinic for Nuclear Medicine, University Hospital of Munich
  • 12/2009Appointment as radiation protection officer at the University Hospital of Munich
  • 2009 - 2013Senior physician at the Clinic and Polyclinic for Nuclear Medicine, Munich University Hospital
  • 2008 - 2009Research stay at the Montréal Neurological Institute (MNI), Brain Imaging Center (BIC), McGill University, Montréal, Canada
  • 11/2007Recognition of the title of specialist in nuclear medicine and the specialist qualification for radiation protection from the Bavarian State Medical Association
  • 05/2003Doctorate at the Clinic and Polyclinic for Nuclear Medicine, University Hospital Munich
  • 2002 - 2008Scientific assistant at the Clinic and Polyclinic for Nuclear Medicine, University Hospital Munich
  • 1995 - 2002Medical studies and practical year at the Ludwig-Maximilians-University Munich and Université Broussais, Paris
  • German Society for Nuclear Medicine (DGN)
  • European Association of Nuclear Medicine (EANM)
  • South-West German Society for Nuclear Medicine (SWDGN)
  • German Society for Endocrinology (DGE)